Evidence map›Paper›PMID 41307765›Full record

ArticleBreast cancer research and treatment2025

Impact of concurrent lobular carcinoma in situ on recurrence outcomes in patients with classic and pleomorphic invasive lobular carcinoma of the breast.

Mandeep Kaur, Astrid Quirarte, Anna Vertido, Taron Torosian, Thomas M Li, Jason A Mouabbi, Rita A Mukhtar

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Breast cancer research and treatment, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Mandeep KaurSchool of Medicine, University of California, San Francisco, CA, USA.
Astrid QuirarteDivision of Surgical Oncology, Department of Surgery, University of California, San Francisco, CA, USA.
Anna VertidoDepartment of Surgery, University of California, San Francisco, CA, USA.
Taron TorosianDepartment of Surgery, University of California, San Francisco, CA, USA.
Thomas M LiDepartment of Surgery, University of California, San Francisco, CA, USA.
Jason A MouabbiDepartment of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Rita A MukhtarDivision of Surgical Oncology, Department of Surgery, University of California, San Francisco, CA, USA. rita.mukhtar@ucsf.edu.

Funding

Identifying responders to chemotherapy in invasive lobular carcinoma of the breast: development of a multivariable clinical prediction toolK08CA256047 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MUKHTAR, RITA · 2021 to 2025
$1.3M
NCI NIH HHS K08 CA256047NCI NIH HHS K08CA256047
6 · The paper itself

Abstract

purposeWe investigated outcomes of invasive lobular carcinoma (ILC) with or without concurrent lobular carcinoma in situ (LCIS) in patients with classic or pleomorphic ILC.

methodsWe retrospectively analyzed a single-institution database of patients with stage I-III ILC. We compared tumor features, treatment, and recurrence free survival (RFS) in patients with ILC-alone versus ILC + LCIS stratified by ILC tumor subtype. Multivariable Cox proportional hazards models were used for multivariate analysis.

resultsOf the 786 cases of ILC, 542 were classic and 92 were pleomorphic, with 70.6% overall having concurrent LCIS. Overall, ILC + LCIS cases were less often T3 (p = 0.037) and had lower rates of N2/N3 disease (p = 0.026) than ILC-alone. Concomitant LCIS was also associated with greater progesterone receptor (PR) positivity (p = 0.016), and was more commonly grade 2 and less often grade 1 compared to ILC-alone (p = 0.008). Treatment differed, with ILC + LCIS cases receiving less chemotherapy (p = 0.016) and more mastectomy (p = 0.015). Among patients with classic ILC, the presence of concomitant LCIS was not associated with different RFS. However, among those with pleomorphic ILC, ILC + LCIS was associated with significantly improved RFS compared to ILC-alone (HR 0.31, 95% confidence interval 0.10-0.96, p = 0.043).

conclusionWhile the presence of LCIS was not associated with RFS in classic ILC in this dataset, it is a favorable prognostic factor in pleomorphic ILC, suggesting a potentially differential role in ILC subtypes.

Indexed as

Breast Carcinoma In SituBreast NeoplasmsCarcinoma, LobularNeoplasm Recurrence, LocalAdultAgedAged, 80 and overFemaleHumansMastectomyMiddle AgedNeoplasm GradingNeoplasm InvasivenessNeoplasm StagingPrognosisProportional Hazards ModelsInvasive lobular carcinomaLobular carcinomaLobular carcinoma in situ

Identifiers

PMID41307765
PMCPMC12660351

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.